文献速递心力衰竭与心肌病心律失常

扩张型心肌病:遗传学作用及FLNC变异家系分析

Dilated cardiomyopathy: the role of genetics, highlighted in a family with Filamin C (FLNC) variant.
PubMed 文献 · Heart · 2021-08-20

扩张型心肌病(DCM)以左室扩张和功能障碍为特征,需排除高血压、瓣膜病或显著冠心病。特发性DCM患病率约为1:250至1:500。文章通过一个携带FLNC变异的家系(表现为年轻猝死和心衰)综述DCM的诊断、治疗、遗传关联及获得性病因,强调基因检测在20%-35%的DCM中呈阳性,有助于家系筛查和风险分层。

要点

  • DCM诊断需排除高血压、瓣膜病和显著冠心病等负荷异常或获得性病因。
  • FLNC变异可导致年轻猝死和心衰,家系筛查有助于识别高危成员。
  • 基因检测在20%-35%的DCM中阳性,应结合遗传咨询用于特定病例。

核心结论

  • DCM病因复杂,遗传因素在部分家系中起关键作用,FLNC变异可导致年轻猝死和严重左室功能障碍。
  • 基因检测在20%-35%的DCM中呈阳性,有助于通过家系筛查识别高危亲属。

研究设计与样本

  • 本文为综述,基于一个携带FLNC变异的DCM家系病例,回顾DCM的诊断、治疗、遗传关联及获得性病因。

主要发现

  • 该家系中FLNC变异与年轻猝死、严重左室功能受损和心肌瘢痕导致的心衰相关。
  • 特发性DCM的患病率估计为1:250至1:500。
  • 基因检测在DCM中阳性率为20%-35%。

关键数值与推荐

  • DCM诊断需在无高血压、瓣膜病或显著冠心病等影响负荷条件或获得性病因的情况下,出现左室扩张和功能障碍。
  • 根据国际指南,全面评估以进行风险分层,识别可能从一级预防植入式心律转复除颤器(ICD)治疗中获益的患者。
  • 基因检测应在特定病例中考虑,并在适当咨询后用于家系筛查。

临床怎么用

  • 对DCM患者应详细评估家族史和获得性病因,以鉴别遗传性病因。
  • 对特定DCM病例考虑基因检测,阳性者进行家系 cascade 筛查。
  • 根据国际指南进行风险分层,评估ICD一级预防适应证。
  • 复杂家系性心肌病的管理需要专科输入和协调检查的基础设施。

局限性

  • 基因检测在DCM中阳性率仅为20%-35%,存在局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Dilated cardiomyopathy (DCM) is a heterogenous group of disorders characterised by left ventricular dilatation and dysfunction, in the absence of factors affecting loading conditions such as hypertension or valvular disease, or significant coronary artery disease. The prevalence of idiopathic DCM is estimated between 1:250 and 1:500 individuals. Determining the aetiology of DCM can be challenging, particularly when evaluating an individual and index case with no classical history or investigations pointing towards an obvious acquired cause, or no clinical clues in the family history to suggest a genetic cause. We present a family affected by DCM associated with Filamin C variant, causing sudden cardiac death at a young age and heart failure due to severe left ventricular impairment and myocardial scarring. We review the diagnosis and treatment of DCM, its genetic associations and potential acquired causes. Thorough assessment is mandatory to risk stratify and identify patients who may benefit from primary prevention implantable cardioverter defibrillator therapy according to international guidelines. Genetic testing has some limitations, and is positive in only 20%-35% of DCM, but should be considered in specific cases to identify families who may benefit from cascade screening after appropriate counselling. The management of often complex familial cardiomyopathy requires specialist input for every case, and the appropriate infrastructure to coordinate investigations.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Dungu JN, Langley SG, Hardy-Wallace A, et al. Dilated cardiomyopathy: the role of genetics, highlighted in a family with Filamin C (FLNC) variant. Heart. 2021. PMID: 34417207. doi:10.1136/heartjnl-2021-319682

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。